General Information of Drug (ID: DMDCHM7)

Drug Name
BMS-986016 Drug Info
Indication
Disease Entry ICD 11 Status REF
Hematologic tumour 2B33.Y Phase 1/2 [1]
Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMDCHM7

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Relatlimab DM28AZV Melanoma 2C30 Approved [3]
Anti-LAG3 DMJO402 Gastric adenocarcinoma 2B72 Phase 2 [4]
IMP-321 DM18ZLW Allergy 4A80-4A85 Phase 1/2 [5]
Favezelimab DMYAIE2 Non-hodgkin lymphoma 2B33.5 Phase 1/2 [6]
XmAb22841 DMQB3HD Solid tumour/cancer 2A00-2F9Z Phase 1 [7]
FS118 DM0QH9K Advanced cancer 2A00-2F9Z Phase 1 [8]
RG6139 DMJFM3O Solid tumour/cancer 2A00-2F9Z Phase 1 [9]
ADPT01 DMS6DPF Breast cancer 2C60-2C65 Phase 1 [10]
IMP-701 DMXSMF9 Solid tumour/cancer 2A00-2F9Z Phase 1 [11]
GSK2831781 DMC47M9 Autoimmune disease 4A40-4A45 Phase 1 [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Lymphocyte activation gene 3 protein (LAG3) TTNVXAW LAG3_HUMAN Modulator [2]

References

1 ClinicalTrials.gov (NCT02061761) Safety Study of Anti-LAG-3 in CLL, HL, NHL and MM. U.S. National Institutes of Health.
2 Nivolumab in NSCLC: latest evidence and clinical potential. Ther Adv Med Oncol. 2015 March; 7(2): 85-96.
3 FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 761234
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 A soluble form of lymphocyte activation gene-3 (IMP321) induces activation of a large range of human effector cytotoxic cells. J Immunol. 2007 Sep 15;179(6):4202-11.
6 A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer. ESMO Open. 2022 Dec;7(6):100639.
7 Clinical pipeline report, company report or official report of Xencor.
8 Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730.
9 Clinical pipeline report, company report or official report of Genentech.
10 Clinical pipeline report, company report or official report of Novartis.
11 IMP321 (sLAG-3), an immunopotentiator for T cell responses against a HBsAg antigen in healthy adults: a single blind randomised controlled phase I study. J Immune Based Ther Vaccines. 2007 Mar 29;5:5.
12 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)